Maurya A K, Singh A K, Kumar M, Umrao J, Kant S, Nag V L, Kushwaha R A S, Dhole T N
Department of Microbiology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, Uttar Pradesh, India.
Indian J Med Microbiol. 2013 Jan-Mar;31(1):40-6. doi: 10.4103/0255-0857.108720.
India has a high burden of drug-resistant tuberculosis (TB), although there is little data on multidrug-resistant tuberculosis (MDR-TB). Although MDR-TB has existed for long time in India, very few diagnostic laboratories are well-equipped to test drug sensitivity. The objectives of this study were to determine the prevalence of MDR-TB, first-line drug resistance patterns and its changing trends in northern India in the 4 years.
This was a prospective study from July 2007 to December 2010. Microscopy, culture by Bactec460 and p-nitro-α-acetylamino-β-hydroxypropiophenone (NAP) test was performed to isolate and identify Mycobacterium tuberculosis (M. tb) complex (MTBC). Drug sensitivity testing (DST) was performed by 1% proportional method (Bactec460) for four drugs: Rifampicin, isoniazid, ethambutol and streptomycin. Various clinical and demographical profiles were evaluated to analyse risk factors for development of drug resistance.
We found the overall prevalence rate of MDR-TB to be 38.8%, increasing from 36.4% in 2007 to 40.8% in 2010. we found that the prevalence of MDR-TB in new and previously treated cases was 29.1% and 43.3% ( P < 0.05; CI 95%). The increasing trend of MDR-TB was more likely in pulmonary TB when compared with extra-pulmonary TB ( P < 0.05; CI 95%).
we found a high prevalence (38.8%) of MDR-TB both in new cases (29.1%) and previously treated cases (43.3%).This study strongly highlights the need to make strategies for testing, surveillance, monitoring and management of such drug-resistant cases.
印度耐药结核病负担沉重,尽管关于耐多药结核病(MDR-TB)的数据很少。虽然MDR-TB在印度已存在很长时间,但很少有诊断实验室具备完善的药物敏感性检测设备。本研究的目的是确定印度北部4年中MDR-TB的患病率、一线耐药模式及其变化趋势。
这是一项从2007年7月至2010年12月的前瞻性研究。通过显微镜检查、Bactec460培养和对硝基-α-乙酰氨基-β-羟基苯丙酮(NAP)试验来分离和鉴定结核分枝杆菌(M. tb)复合体(MTBC)。采用1%比例法(Bactec460)对利福平、异烟肼、乙胺丁醇和链霉素四种药物进行药物敏感性试验(DST)。评估各种临床和人口统计学特征以分析耐药发生的危险因素。
我们发现MDR-TB的总体患病率为38.8%,从2007年的36.4%上升至2010年的40.8%。我们发现新发病例和既往治疗病例中MDR-TB的患病率分别为29.1%和43.3%(P<0.05;95%CI)。与肺外结核相比,肺结核中MDR-TB的上升趋势更明显(P<0.05;95%CI)。
我们发现新发病例(29.1%)和既往治疗病例(43.3%)中MDR-TB的患病率都很高。本研究强烈强调需要制定针对此类耐药病例的检测、监测、监控和管理策略。